EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudieStudienprotokollOpen Access

Protocol of the Comparison of Two Different Bicarbonate Replacement Fluids during Continuous Veno-Venous Hemofiltration with Regional Citrate Anticoagulation: A Prospective, Randomized, Controlled Trial

Paul Köglberger, Fabian Perschinka, Sebastian J Klein, Timo Mayerhöfer, Sarah Maier, Hanno Ulmer, Romuald Bellmann, Michael Joannidis

Blood Purification · 2025

DOI: 10.1159/000547401 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Blood Purification, 2025. Verfasst von Paul Köglberger und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria. Hauptthemen laut MEDLINE: Bicarbonates, Anticoagulants, Continuous Renal Replacement Therapy, Citric Acid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Acid-base disturbances are common issues during continuous veno-venous hemofiltration (CVVH). Especially using regional citrate anticoagulation (RCA), recent studies have shown that control in intracorporal pH and HCO3 concentration may be improved when the replacement fluid is changed to a solution with a lower HCO3− concentration during continuous renal replacement therapy. This prospective trail aimed to compare acid-base balance between a high (HBF) and low (LBF) bicarbonate replacement fluid over a period of 96 h after CVVH initiation using RCA.

Methods

This is a prospective, randomized, controlled, open-label, crossover, phase II, single-center study involving critically ill patients requiring RRT. The two replacement fluids (Phoxilium and Biphozyl) are compared in two groups with 1:1 block randomization and consecutive crossover after 48 h of CVVH. The primary endpoints are the occurrence of at least one pH (>7.45) or HCO3− (>26 mmol/L) excursion within 16–48 h of each treatment phase using a generalized estimating equation approach. The objective was to examine differences of pH and HCO3− between patients who receive LBF and HBF as replacement fluid during CVVH. We hypothesize that during CVVH with LBF, pH, and HCO3− excursion rates are significantly lower compared to HBF. Recruitment of 88 study participants is ongoing, with the trial expected to be completed in 2025. Data cleaning, analysis, and publication preparation will follow thereafter. The trial is registered at ClinicalTrials.gov (NCT04071171) and EudraCT (2019-001262-15).

Conclusion

Given the broad inclusion and restricted exclusion criteria, we expect the results of the BiPhox-Trial to be broadly applicable to patients in need of CVVH with RCA in the intensive care setting. This trial aims to determine whether the use of LBF results in more stable acid-base parameters compared to HBF during CVVH with RCA in critically ill patients and may guide therapeutic decisions in clinical practice.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

BicarbonatesAnticoagulantsContinuous Renal Replacement TherapyCitric AcidHemofiltrationHumansProspective StudiesMaleFemaleAcid-Base EquilibriumMiddle AgedAged

Stichwörter der Autor:innen

Acid-base profileAcute kidney injuryClinical outcomes researchRenal replacement therapyReplacement fluids

Substanzen

BicarbonatesAnticoagulantsCitric Acid

Autor:innen und Institutionen

  • Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria.
  • Institute of Anesthesiology and Critical Care Medicine, Klinikum Wels, Wels, Austria.
  • Institute of Clinical Epidemiology, Public Health, Health Economics, Medical Statistics and Informatics, Medical University Innsbruck, Innsbruck, Austria.
  • Division of Intensive Care and Emergency Medicine, Department of Internal Medicine, Medical University Innsbruck, Innsbruck, Austria, michael.joannidis@i-med.ac.at.

Zitieren

APA

Köglberger, P., Perschinka, F., Klein, S. J., Mayerhöfer, T., Maier, S., Ulmer, H., Bellmann, R., & Joannidis, M. (2025). Protocol of the Comparison of Two Different Bicarbonate Replacement Fluids during Continuous Veno-Venous Hemofiltration with Regional Citrate Anticoagulation: A Prospective, Randomized, Controlled Trial. Blood Purification. https://doi.org/10.1159/000547401

Vancouver

Köglberger P, Perschinka F, Klein SJ, Mayerhöfer T, Maier S, Ulmer H, et al. Protocol of the Comparison of Two Different Bicarbonate Replacement Fluids during Continuous Veno-Venous Hemofiltration with Regional Citrate Anticoagulation: A Prospective, Randomized, Controlled Trial. Blood Purification. 2025. doi:10.1159/000547401

BibTeX
@article{Kglberger2025,
  author = {Köglberger, Paul and Perschinka, Fabian and Klein, Sebastian J and Mayerhöfer, Timo and Maier, Sarah and Ulmer, Hanno and Bellmann, Romuald and Joannidis, Michael},
  title = {Protocol of the Comparison of Two Different Bicarbonate Replacement Fluids during Continuous Veno-Venous Hemofiltration with Regional Citrate Anticoagulation: A Prospective, Randomized, Controlled Trial},
  journal = {Blood Purification},
  year = {2025},
  doi = {10.1159/000547401}
}
Kostenlos starten →